Richard C. Young & CO. LTD. Cuts Stock Holdings in Pfizer Inc. $PFE

Key Points

• Richard C. Young & CO. LTD. trimmed its Pfizer stake by 55.9% in Q4, selling 249,359 shares and leaving 197,058 shares worth $4.907 million.
• Pfizer declared a quarterly dividend of $0.43 (annualized $1.72) with an ex-dividend date of May 8 and a yield of 6.4%, though the payout ratio is elevated at 126.47%.
• Pfizer beat Q4 expectations with EPS $0.66 vs. $0.57 consensus and revenue of $17.56B, and the company cites pipeline momentum (GLP‑1 programs and the Seagen acquisition) as potential drivers of future growth.

Richard C. Young & CO. LTD. trimmed its stake in shares of Pfizer Inc. (NYSE:PFE - Free Report) by 55.9% in the 4th quarter, according to its most recent disclosure with the SEC. The institutional investor owned 197,058 shares of the biopharmaceutical company's stock after selling 249,359 shares during the period. Richard C. Young & CO. LTD.'s holdings in Pfizer were worth $4,907,000 at the end of the most recent quarter.

Other institutional investors also recently bought and sold shares of the company. Brighton Jones LLC grew its stake in shares of Pfizer by 1,282.4% in the 4th quarter. Brighton Jones LLC now owns 666,318 shares of the biopharmaceutical company's stock worth $17,677,000 after buying an additional 618,117 shares in the last quarter. Revolve Wealth Partners LLC grew its stake in shares of Pfizer by 12.5% in the 4th quarter. Revolve Wealth Partners LLC now owns 18,766 shares of the biopharmaceutical company's stock worth $498,000 after buying an additional 2,087 shares in the last quarter. United Bank grew its stake in shares of Pfizer by 12.4% in the 2nd quarter. United Bank now owns 58,087 shares of the biopharmaceutical company's stock worth $1,408,000 after buying an additional 6,415 shares in the last quarter. Sei Investments Co. grew its stake in shares of Pfizer by 31.5% in the 2nd quarter. Sei Investments Co. now owns 2,635,691 shares of the biopharmaceutical company's stock worth $63,889,000 after buying an additional 631,523 shares in the last quarter. Finally, HUB Investment Partners LLC grew its stake in shares of Pfizer by 45.3% in the 2nd quarter. HUB Investment Partners LLC now owns 102,327 shares of the biopharmaceutical company's stock worth $2,480,000 after buying an additional 31,896 shares in the last quarter. 68.36% of the stock is owned by hedge funds and other institutional investors.

Pfizer Price Performance

PFE stock opened at $27.01 on Friday. Pfizer Inc. has a 12 month low of $21.97 and a 12 month high of $28.75. The company has a current ratio of 1.16, a quick ratio of 0.87 and a debt-to-equity ratio of 0.71. The company has a 50-day moving average price of $27.23 and a 200 day moving average price of $26.06. The stock has a market cap of $153.56 billion, a PE ratio of 19.86 and a beta of 0.43.

Pfizer (NYSE:PFE - Get Free Report) last released its quarterly earnings results on Tuesday, February 3rd. The biopharmaceutical company reported $0.66 EPS for the quarter, topping analysts' consensus estimates of $0.57 by $0.09. Pfizer had a net margin of 12.42% and a return on equity of 20.48%. The firm had revenue of $17.56 billion during the quarter, compared to analysts' expectations of $16.93 billion. During the same period in the previous year, the company earned $0.63 EPS. The firm's revenue for the quarter was down 1.2% compared to the same quarter last year. Equities research analysts anticipate that Pfizer Inc. will post 2.98 earnings per share for the current year.

Pfizer Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Friday, June 12th. Investors of record on Friday, May 8th will be paid a dividend of $0.43 per share. The ex-dividend date of this dividend is Friday, May 8th. This represents a $1.72 dividend on an annualized basis and a dividend yield of 6.4%. Pfizer's payout ratio is currently 126.47%.

Key Stories Impacting Pfizer

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Board declared a $0.43 Q2 dividend (payable June 12; ex-div May 8), reinforcing Pfizer’s long track record of income (350th consecutive quarterly dividend) and supporting demand from income-minded investors. Pfizer Declares Second-Quarter 2026 Dividend
• Positive Sentiment: Seagen acquisition appears to be contributing to growth and a stronger oncology franchise (Antibody‑Drug Conjugates), supporting medium-term revenue upside as Pfizer expands cancer capabilities. Pfizer Inc. (PFE): One of the Best Safe Stocks to Invest in for Beginners
• Positive Sentiment: GLP‑1 obesity program momentum — Phase 2b monthly GLP‑1 data and plans for a large clinical program provide optionality beyond legacy drugs and could open a new growth engine if later‑stage trials succeed. Pfizer’s Monthly GLP-1 Push Tests Balance Between Obesity Growth And Dividends
• Positive Sentiment: Multiple early‑stage pipeline advances (completion of a China Phase 1 for a heart‑failure candidate, new gastric‑emptying study for an obesity asset, new Phase 1 cancer and liver studies) add cadence and long‑term upside to the pipeline. Pfizer Advances Early-Stage Heart Failure Candidate With Completion Of Chinese Phase 1 Study
• Neutral Sentiment: Pfizer released results from its 2026 shareholder meeting — largely procedural items that don’t materially change near‑term fundamentals. Pfizer Unveils 2026 Shareholder Meeting Results
• Neutral Sentiment: Bristol Myers and Pfizer will make Eliquis available through Mark Cuban’s Cost Plus pharmacy starting April 27 — improves patient access but raises questions about pricing/volume tradeoffs; watch margin impact. Bristol Myers, Pfizer to offer blockbuster blood thinner through Mark Cuban's online pharmacy
• Neutral Sentiment: Broader industry news — competitors (e.g., Eli Lilly, Novo Nordisk) continue to shape the obesity/GLP‑1 landscape; this is both competitive risk and market validation for Pfizer’s obesity push. Eli Lilly's new GLP-1 pill vs. Wegovy, JPMorgan initiates coverage on Hims
• Negative Sentiment: Pfizer ended a Phase 1 cancer trial, trimming part of its oncology pipeline — a reminder that not all program investments convert to later‑stage value and a near‑term negative headline. Pfizer Ends Early-Stage Cancer Trial, Trimming Its Oncology Pipeline
• Negative Sentiment: Analyst skepticism persists (Barclays remains negative; consensus leans to “hold”), which can cap upside until clearer revenue/cost trajectories emerge. Barclays Remains a Sell on Pfizer (PFE)

Analyst Ratings Changes

A number of equities analysts have commented on the stock. Royal Bank Of Canada reissued an "underperform" rating and issued a $25.00 price objective on shares of Pfizer in a research note on Monday, April 20th. Argus raised shares of Pfizer from a "hold" rating to a "buy" rating and set a $35.00 price objective for the company in a research note on Monday, March 2nd. Cantor Fitzgerald reissued a "neutral" rating and issued a $27.00 price objective on shares of Pfizer in a research note on Wednesday, February 4th. UBS Group lifted their price objective on shares of Pfizer from $25.00 to $27.00 and gave the stock a "neutral" rating in a research note on Monday, April 13th. Finally, Zacks Research raised shares of Pfizer from a "strong sell" rating to a "hold" rating in a research note on Tuesday, February 24th. One analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, fourteen have issued a Hold rating and three have given a Sell rating to the company's stock. According to MarketBeat, the company has a consensus rating of "Hold" and a consensus target price of $28.48.

Pfizer Company Profile

Pfizer Inc NYSE: PFE is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer's portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.

Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.